Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$6.73M

FY 2025 · Annual

Investing Cash Flow

-$17.37M

FY 2025 · Annual

Financing Cash Flow

$266.84M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.75M)(61.62M)(38.35M)(21.44M)(209.84M)
Depreciation & Amortization441K490K830K181K34K
Deferred Income Tax00000
Stock-Based Compensation0000998K
Change in Working Capital(6.62M)11.94M(4.37M)(2.67M)18.36M
Accounts Receivables00000
Inventory00000
Accounts Payables(1.32M)1.82M(1.65M)(1.33M)17.27M
Other Working Capital(5.3M)10.12M(2.72M)(1.34M)1.09M
Other Non-Cash Items5.63M6.27M4.98M5.3M183.72M
Operating Cash Flow(52.31M)(42.93M)(36.91M)(18.62M)(6.73M)
Capital Expenditures(223K)(196K)000
Acquisitions (Net)0083K0(17.37M)
Purchases of Investments(84.21M)(44.87M)(25.94M)00
Sales of Investments36.38M57.45M48.18M11.65M0
Other Investing Activities00000
Investing Cash Flow(48.05M)12.38M22.33M11.65M(17.37M)
Debt Repayment00000
Common Stock Issued0507K2.88M00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000033K
Financing Cash Flow0507K2.88M0266.84M
Effect of Forex Changes(663K)264K384K(317K)705K
Net Change in Cash(101.02M)(29.78M)(11.32M)(7.29M)243.45M
Free Cash Flow(52.53M)(43.13M)(36.91M)(18.62M)(6.73M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$209.8M
+ D&A$34.0K
+ Stock-Based Comp$998.0K
+ Deferred Tax$0
+ Working Capital$18.4M
+ Other Non-Cash$183.7M
= Operating Cash Flow-$6.7M
- Capex$0
= Free Cash Flow-$6.7M

Analysis

FY2025 free cash flow is -$6.7M. FCF conversion is 3.2% of net income. Operating cash flow was -$6.7M, with capex of $0. The largest bridge item is Other Non-Cash at $183.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipSep 28, 2026
4Statement of changes in beneficial ownershipAug 13, 2026
3Initial statement of beneficial ownershipAug 13, 2026
EFFECTEFFECT filingAug 12, 2026

Does DMRA generate free cash flow?

Damora Therapeutics, Inc. (DMRA) generated -$6.73M of free cash flow in fiscal 2025.

How much operating cash flow does DMRA produce?

Operating cash flow was -$6.73M, before capital expenditures of $0.00.